medigraphic.com
ISSN 1561-3038 (Print)

2022, Number 1

<< Back Next >>

Rev Cubana Med Gen Integr 2022; 38 (1)

Relationship between diabetes mellitus and cancer

Hernández-García F, Lazo HLA

Language: Spanish
References: 51
Page: 1-22
PDF size: 754.39 Kb.


ABSTRACT

Introduction: Diabetes mellitus and cancer are two health problems affecting the world population. Prior consideration of the risk for cancer development in patients with diabetes mellitus can contribute significantly to its prevention in this risk group.
Objective: To describe the relationship between diabetes mellitus and cancer.
Methods: A literature review was carried out between September 2019 and March 2020. Scientific articles were consulted in Pubmed; the search strategy was defined as it follows: “diabetes mellitus”[Mesh] OR “diabetes mellitus”[TIAB] OR “diabetes mellitus, type 2”[Mesh] OR “type 2 diabetes mellitus”[TIAB] OR obesity[Mesh] OR obesity[TIAB] OR hyperglycemia[Mesh] OR hyperglycemia[TIAB]) AND (cancer[Mesh] OR cancer[TIAB] OR neoplasia[Mesh] OR neoplasia[TIAB] OR neoplasias[Mesh] OR neoplasias[TIAB] OR neoplasm[Mesh] OR neoplasm[TIAB] OR tumors[Mesh] OR tumors[TIAB] OR tumor[Mesh] OR tumor[TIAB] OR cancers[Mesh] OR cancers[TIAB]). Articles from SCOPUS, Scielo, LILACS, the Virtual Health Library of Cuba, and Google Scholar were also reviewed. Articles published from 2005 onwards were selected, with 63% from the last five years (2016-2020). Fifty-one publications were analyzed.
Conclusions: There is consensus regarding the relationship between diabetes and cancer. Diabetes mellitus is a risk factor for the development of cancer, fundamentally in the locations of pancreas, kidney, colon and rectum, as well as the uterine body, ovaries and breast in women; while being a protective factor for prostate cancer in men. Both diseases share nonmodifiable risk factors (age and sex), modifiable risk factors (diet, physical activity, alcoholism, among others) and biological conditions (hyperglycemia and hyperinsulinemia).


REFERENCES

  1. OMS. Informe mundial sobre la diabetes. Resumen de orientación. Ginebra: OMS; 2016 [acceso: 10/12/2019]. Disponible en: Disponible en: http://www.who.int/diabetes/global-report

  2. International Diabetes Federation. IDF Diabetes Atlas, 9th ed. Brussels, Belgium: International Diabetes Federation; 2019 [acceso: 10/01/2020]. Disponible en: Disponible en: https://diabetesatlas.org/atlas/ninth-edition/

  3. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Research and Clinical Practice. 2019;157:107843. DOI: https://doi.org/10.1016/j.diabres.2019.107843

  4. Ministerio de Salud Pública. Dirección de Registros Médicos y Estadísticas de Salud. Anuario Estadístico de Salud 2018. La Habana: MINSAP; 2019 [acceso: 10/12/2019]. Disponible en: Disponible en: http://www.bvscuba.sld.cu/2017/11/20/anuario-estadistico-de-salud-de-cuba/

  5. Cavalli F. Cáncer, el gran desafío. La Habana: Editorial Ciencias Médicas; 2012.

  6. Real Arribas FX, López Otín C. Genes, herencia y cáncer. En: Rozman Borstnar C, Cardellach López F, editores. Medicina Interna. 2016 [acceso: 10/12/2019]. p. 1191-202. Disponible en: Disponible en: https://www.clinicalkey.es/#!/content/book/3-s2.0-B9788490229965001502/

  7. Marks AD, Lieberman M, Peet A. The molecular biology of cancer. En: Marks Basic Medical Biochemistry a Clinical Approach. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2018. p. 759-812.

  8. Barrios E, Garau M. Cáncer: magnitud del problema en el mundo y en Uruguay, aspectos epidemiológicos. Anfamed. 2017;4(1):7-161. DOI: http://dx.doi.org/10.25184/anfamed2017.4.1.2

  9. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016 [acceso: 10/12/2019];388:1459-544. Disponible en: Disponible en: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31012-1/fulltext

  10. McGuire S. World Cancer Report 2014. Geneva: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr. 2016 [acceso: 10/12/2019];7(2):418-9. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4785485/#__ffn_sectitle

  11. WHO. International Agency for Research on Cancer. The Global Cancer Observatory. 2019 [acceso: 10/12/2019]. Disponible en: Disponible en: https://gco.iarc.fr/today/fact-sheets-population

  12. Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015 [acceso: 10/12/2019];350:g7607. Disponible en: Disponible en: https://www.bmj.com/content/350/bmj.g7607

  13. Bellastella G, Scappaticcio L, Esposito K, Giugliano D, Maiorino MI. Metabolic syndrome and cancer: “The common soil hypothesis.” Diabetes Res Clin Pract. 2018 [acceso: 10/12/2019];143:389-97. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/29807099

  14. Cignarelli A, Genchi VA, Caruso I, Natalicchio A, Perrini S, Laviola L, et al. Diabetes and cancer: Pathophysiological fundamentals of a “dangerous affair.” Diabetes Res Clin Pract. 2018 [acceso: 10/12/2019];143:378-88. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/29679627

  15. Duarte MJ, Romero FS, Espinosa LRF, Sánchez RG. Diabetes y cáncer ¿es real la asociación? Med Int Méx. 2016 [acceso: 10/12/2019];32(3):318-29. Disponible en: Disponible en: https://www.medigraphic.com/pdfs/medintmex/mim-2016/mim163g.pdf

  16. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care. 2014 [acceso: 10/12/2019];37(Suppl 1):S14-80. Disponible en: Disponible en: https://care.diabetesjournals.org/content/37/Supplement_1/S14

  17. Ovalle-Luna OD, Jiménez-Martínez IA, Rascón-Pacheco RA, Gómez-Díaz RA, Valdez-González AL, Gamiochipi-Cano M, et al. Prevalencia de complicaciones de la diabetes y comorbilidades asociadas en medicina familiar del Instituto Mexicano del Seguro Social. Gac Med Mex. 2019 [acceso: 10/12/2019];155:30-8. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/30799453

  18. Pearson-Stuttard J, Zhou B, Kontis V, Bentham J, Gunter MJ, Ezzati M. Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. Lancet Diabetes Endocrinol. 2018 [acceso: 10/12/2019];6(2):95-104. Disponible en: Disponible en: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(18)30150-5/fulltext

  19. Ballotari P, Vicentini M, Manicardi V, Gallo M, Chiatamone Ranieri S, Greci M, et al. Diabetes and risk of cancer incidence: results from a population-based cohort study in northern Italy. BMC Cancer. 2017 [acceso: 10/12/2019];17:703. DOI: DOI: https://doi.org/10.1186/s12885-017-3696-4

  20. Huxley R, Ansary-Moghaddam A, Berrington de González A, Barzi F, Woodward M. 21. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Brit J Cancer. 2005 [acceso: 10/12/2019];92:2076-83. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/15886696

  21. Tseng C-H. Type 2 Diabetes Mellitus and Kidney Cancer Risk: A Retrospective Cohort Analysis of the National Health Insurance. PLoS ONE. 2015;10(11):e0142480. DOI: https://doi.org/10.1371/journal.pone.0142480

  22. Kramer HU, Schottker B, Raum E, Brenner H. Type 2 diabetes mellitus and colorectal cancer: Meta-analysis on sex-specific differences. Eur J Cancer. 2012;48:1269-82. DOI: https://doi.org/10.1016/j.ejca.2011.07.010

  23. Saed L, Varse F, Baradaran HR, Moradi Y, Khateri S, Friberg E. The effect of diabetes on the risk of endometrial Cancer: an updated a systematic review and meta-analysis. BMC Cancer. 2019;19:527. Disponible en: https://doi.org/10.1186/s12885-019-5748-4

  24. Wang L, Wang L, Zhang J, Wang B, Liu H. Association between diabetes mellitus and subsequent ovarian cancer in women. A systematic review and meta-analysis of cohort studies. Medicine. 2017;96:16. DOI: http://dx.doi.org/10.1097/MD.0000000000006396

  25. Xiao-Lei W, Cun-Xian J, Li-Yuan L, Qiang Z, Yu-Yang Li, Liang L. Obesity, diabetes mellitus, and the risk of female breast cancer in Eastern China. World J Surgical Oncol. 2013 [acceso: 10/12/2019];11:71. Disponible en: Disponible en: http://www.wjso.com/content/11/1/71

  26. García-Esquinas E, Guinó E, Castaño-Vinyals G, Pérez-Gómez B, Llorca J, Altzibar JM, et al. Association of diabetes and diabetes treatment with incidence of breast cancer. Acta Diabetol. 2016;53:99-107. DOI: https://doi.org/10.1007/s00592-015-0756-6

  27. Tseng C-H. Diabetes but Not Insulin Increases the Risk of Lung Cancer: A Taiwanese Population-Based Study. PLoS ONE. 2014;9(7):e101553. DOI: https://doi.org/10.1371/journal.pone.0101553

  28. Ohkuma T, Sanne A, Peters E, Woodward M. Sex differences in the association between diabetes and cancer: a systematic review and meta-analysis of 121 cohorts including 20 million individuals and one million events. Diabetologia. 2018 [acceso: 10/12/2019];61:2140-54. Disponible en: Disponible en: https://link.springer.com/article/10.1007 %2Fs00125-018-4664-5

  29. Xin Xu, Jian Wu, Yeqing Mao, Yi Zhu, Zhenghui Hu, Xianglai Xu, et al. Diabetes Mellitus and Risk of Bladder Cancer: A Meta-Analysis of Cohort Studies. PLoS One. 2013 [citado 10 Dic 2019];8(3):e58079. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589481/

  30. Zhi-Feng M, Hao X, Ying-Ying X, Zhen-Ning W, Ting-Ting Z, Yong-X S, Hui-Mian X. Diabetes mellitus and the risk of gastric cancer: a meta-analysis of cohort studies. Oncotarget. 2017 [acceso: 10/12/2019];8(27):44881-92. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546528/pdf/oncotarget-08-44881.pdf

  31. Bansal D, Bhansali A, Kapil G, Undela K, Tiwari P. Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer and Prostatic Disease. 2013;16:151-8. Disponible en: https://doi.org/10.1038/pcan.2012.40

  32. Meyer TE, Boerwinkle E, Morrison AC, Volcik KA, Sanderson M, Coker AL, et al. Diabetes genes and prostate cancer in the Atherosclerosis Risk in Communities study. Cancer Epidemiol Biomarkers Prev. 2010;19:558-65. DOI: http://doi.org/10.1158/1055-9965.EPI-09-0902

  33. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and Cancer. A consensus report. Diabetes Care. 2010;33(7):1674-1685. DOI: http://doi.org/10.2337/dc10-0666

  34. Sociedad Americana Contra El Cáncer. Datos y Estadísticas sobre el Cáncer entre los Hispanos/Latinos 2018-2020. Atlanta: Sociedad Americana Contra El Cáncer; 2018 [acceso: 10/12/2019]. Disponible en: Disponible en: https://www.cancer.org/es/investigacion/datos-y-estadisticas-sobre-el-cancer-entre-los-hispanos.html

  35. Carreras-Torres R, Johansson M, Gaborieau V, Haycock PC, Wade KH, Relton CL, et al. The Role of Obesity, Type 2 Diabetes, and Metabolic Factors in Pancreatic Cancer: A Mendelian Randomization Study. J Natl Cancer Inst. 2017 [acceso: 10/12/2019];109(9):djx012. Disponible en: Disponible en: https://academic.oup.com/jnci/article/109/9/djx012/3778207

  36. Collins KK. The Diabetes-Cancer Link. Diabetes Spectrum. 2014;27(4):276-80. DOI: https://doi.org/10.2337/diaspect.27.4.276

  37. Herrera-Covarrubias D, Coria-Avila GA, Fernández-Pomares C, Aranda-Abreu GE, Manzo Denes J, Hernández ME. La obesidad como factor de riesgo en el desarrollo de cáncer. Rev Peru Med Exp Salud Pública. 2015 [acceso: 10/12/2019];32(4):766-76. Disponible en: Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1726-46342015000400021

  38. Bishehsari F, Mahdavinia M, Vacca M, Malekzadeh R, Mariani-Costantini R. Epidemiological transition of colorectal cancer in developing countries: Environmental factors, molecular pathways, and opportunities for prevention. World J. Gastroenterol. 2014;20(20): 6055-72. DOI: http://doi.org/10.3748/wjg.v20.i20.6055

  39. American Diabetes Association. 5. Facilitating behavior change and wellbeing to improve health outcomes: Standards of Medical Care in Diabetes 2020. Diabetes Care. 2020;43(Suppl 1):S48-S65. DOI: https://doi.org/10.2337/dc20-S005

  40. Patterson R, McNamara E, Tainio M, Hérick de Sá T, Smith AD, Sharp SJ, et al. Sedentary behaviour and risk of all-cause, cardiovascular and cancer mortality, and incident type 2 diabetes: a systematic review and dose response meta-analysis. Eur J Epidemiol. 2018;33:811-29. DOI: https://doi.org/10.1007/s10654-018-0380-1

  41. World Cancer Leaders’ Summit. The Economics of Cancer Prevention& Control Data Digest. Union for International Cancer Control. Switzerland; 2014 [acceso: 10/12/2019]. Disponible en: Disponible en: http://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014

  42. American Diabetes Association. 3. Prevention or delay of type 2 diabetes: Standards of Medical Care in Diabetes 2020. Diabetes Care. 2020;43(Suppl. 1):S32-S36. DOI: https://doi.org/10.2337/dc20-S003

  43. Secretan B, Straif K, Baan R, Grosse Y, El Ghissassi F, Bouvard V, et al. WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens-Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol. 2009;10:1033-4. DOI: https://doi.org/10.1016/S1470-2045(09)70326-2

  44. Nubiola A, Ferrer M, Remolins I. La asociación de hiperinsulinemia con riesgo cardiovascular y cáncer plantea nuevos retos en el abordaje del paciente con diabetes tipo 2, insulinorresistente. Hipertens Riesgo Vasc. 2014;32(1):21-6. Disponible en: http://dx.doi.org/10.1016/j.hipert.2014.06.001

  45. Arcidiacono B, Liritiano S, Nocera A, Posidente K, Nevolo M, Ventura V. Insulin resistance and cancer risk: An overview of the pathogenetic mechanisms. Exp Diabetes Res. 2012. DOI: https://doi.org/10.1155/2012/789174

  46. Villegas Valverde CA, Frontela Noda M, García Figueredo I. Nuevas evidencias del uso de la metformina en el tratamiento del cáncer. Rev Cubana Endocrinol. 2016 [acceso: 10/12/2019];27(3):80-90. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532016000300008&lng=es

  47. Bowker S, Majumdar S, Veugelers P, Johnson JA. Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin. Diabetes Care. 2006 [acceso: 10/12/2019];29(2). Disponible en: Disponible en: https://care.diabetesjournals.org/content/29/2/254

  48. Ramjeesingh R, Orr C, Bricks CS, Hopman WM, Hammad N. A retrospective study on the role of diabetes and metformin in colorectal cancer disease survival. Curr Oncol. 2016;23(2):e116-e122. DOI: http://dx.doi.org/10.3747/co.23.2809

  49. Baglia ML, Yong C, Tao Z, Gong Y, Honglan L, Mingrong Y, et al. Diabetes Medication Use in Association with Survival among Patients of Breast, Colorectal, Lung, or Gastric Cancer. Cancer Res Treat. 2019;51(2):538-46. DOI: https://doi.org/10.4143/crt.2017.591

  50. Yeo Jin C, Dae Jung K, Sooyoung S. Incident cancer risk in dipeptidyl peptidase-4 inhibitor-treated patients with type 2 diabetes mellitus. Cancer Management Res. 2019;11:7427-38. DOI: https://doi.org/10.2147/CMAR.S215107

  51. Cuevas Valdespino IE. Personal Responsibility in a Universal Health System. MEDICC Rev. 2017 [acceso: 10/12/2019];19(4):5. Disponible en: Disponible en: https://www.medigraphic.com/pdfs/medicreview/mrw-2017/mrw174b.pdf




2020     |     www.medigraphic.com